GND-02

GND-02 is a preclinical-stage therapeutic candidate being developed by Gandeeva Therapeutics for the treatment of unspecified oncology indications. It is part of the company's proprietary iGlue™ platform, which integrates artificial intelligence and cryogenic electron microscopy (cryo-EM) to design molecular glues for previously inaccessible biological targets. GND-02 is specifically categorized as a gain-of-function asset, meaning it is designed to stabilize or enhance specific protein-protein interactions to achieve a therapeutic effect. As of early 2024, the specific molecular target of GND-02 remains undisclosed, and the program is in the discovery and optimization phase.